← Back to Search

NightOwl for Sleep Apnea

N/A
Waitlist Available
Led By Jagdeep Bijwadia, MD MBA
Research Sponsored by Ectosense NV
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with an indication for an in-lab polysomnography
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 month.
Awards & highlights

Study Summary

This study is evaluating whether a new device may be able to detect sleep apnea.

Eligible Conditions
  • Sleep Apnea

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 month.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 month. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The Evaluation of the Level of Agreement (Classification Accuracy) Between Patient Categorization

Trial Design

1Treatment groups
Experimental Treatment
Group I: PSG and NightOwlExperimental Treatment1 Intervention
During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with the informed consent form. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NightOwl
2019
N/A
~240

Find a Location

Who is running the clinical trial?

Ectosense NVLead Sponsor
6 Previous Clinical Trials
1,224 Total Patients Enrolled
3 Trials studying Sleep Apnea
1,056 Patients Enrolled for Sleep Apnea
Jagdeep Bijwadia, MD MBAPrincipal InvestigatorSleepMed RX

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~24 spots leftby Apr 2025